On July 16, 2025, the Paytm parent company, One 97 Communications, saw its stock price rise by 2.03% in early trading. This slight jump grabbed attention across the market. Investors are now asking: What’s behind the bounce?
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Italy stands at a critical crossroads. The nation could lose €20 billion ($23.6 billion) in exports and 118,000 jobs if the United States slaps 10% tariffs on European goods. Confindustria President Emanuele Orsini sounded the alarm on July 2, calling these tariffs unsustainable for Italy’s economy. Continue Reading on Meyka This article is available in…
The global fintech sector is watching closely as PayPay, the Japanese digital payments platform backed by SoftBank, prepares for a major public listing in the United States. The upcoming offering could become one of the most discussed fintech IPOs of the year, but reports suggest the company may price its shares at the lower end…
The Superannuation shake up aims to protect retirees by reducing the risk of large retirement savings losses, improving oversight, and reshaping how Australians manage their retirement funds. The changes focus on fairer tax settings, more personal financial control, and better long term outcomes for retirement savings. Continue Reading on Meyka This article is available in…
Gmail is not just another email service. It is the world’s largest email platform with more than 1.8 billion users worldwide. We use it every day to sign in to apps, recover accounts, share files, and even manage money matters. That is exactly why experts are raising alarms right now after getting Gmail News Today;…
Intel remains a cornerstone of the stock market, driving innovation in semiconductors and technology. Mizuho, a leading financial firm, recently raised its price target for Intel (NASDAQ: INTC) to $23 from $22, signaling confidence in the company’s direction under new leadership. This adjustment, paired with Intel’s strategic moves in AI, 5G, and advanced manufacturing, offers…
We are witnessing a significant shift in the pharmaceutical landscape as Mounjaro, a weight-loss treatment developed by Eli Lilly, faces escalating demand and limited availability in the UK. The company’s decision to pause shipments to Britain has sparked widespread concern among patients and healthcare providers. Continue Reading on Meyka This article is available in full…